|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||521.74 - 530.25|
|52-week range||309.38 - 540.06|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||8.17|
|Earnings date||29 Oct 2020 - 02 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||603.75|
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld the lower Court’s finding on monetary damages amounting to $23.9 million at the time of the trial, November 2018, awarding Bio-Rad a 15 percent royalty on past and future sales, and a permanent injunction against 10x’s Single Cell 3’ Gene Expression products, Single Cell ATAC-seq products, and Single Cell V(D)J products that were found to infringe the ‘083 patent.
Ladies and gentlemen, thank you for standing by, and welcome to the Q2 2020 Bio-Rad Laboratories, Inc. Earnings Conference Call. Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other matters.
Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.